{"id":134608,"date":"2026-07-24T11:21:12","date_gmt":"2026-07-24T11:21:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/134608\/"},"modified":"2026-07-24T11:21:12","modified_gmt":"2026-07-24T11:21:12","slug":"legal-showdown-novo-nordisk-vs-eli-lilly-in-drug-advertising-battle","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/134608\/","title":{"rendered":"Legal Showdown: Novo Nordisk vs. Eli Lilly in Drug Advertising Battle"},"content":{"rendered":"<p>In a legal twist, Novo Nordisk seeks to block Eli Lilly&#8217;s advertisements for obesity and diabetes drugs in the U.S. Novo argues the ads mislead consumers by comparing outdated studies, warranting a preliminary injunction to prevent misinformation.<\/p>\n<p>Eli Lilly stands by its advertising practices, rejecting claims of misinformation. As both pharmaceutical giants vie for dominance in the booming obesity drug market, expected to exceed $100 billion by decade&#8217;s end, Novo accuses Lilly&#8217;s ads of giving a false impression.<\/p>\n<p>Novo&#8217;s lawsuit highlights unfair competition and false advertising, demanding Eli Lilly withdraw its campaigns and issue corrective ads. The case underscores Novo&#8217;s determination to aggressively manage its business and public perception. Analyst Evan Seigerman notes Novo&#8217;s sharpened competitive strategy.<\/p>\n<p>(With inputs from agencies.)<\/p>\n","protected":false},"excerpt":{"rendered":"In a legal twist, Novo Nordisk seeks to block Eli Lilly&#8217;s advertisements for obesity and diabetes drugs in&hellip;\n","protected":false},"author":2,"featured_media":134609,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[65313,65315,18205,276,620,25222,272,9754,65280,65314],"class_list":["post-134608","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-advertising-lawsuit","tag-consumer-misinformation","tag-diabetes-treatment","tag-eli-lilly","tag-legal-action","tag-market-competition","tag-novo-nordisk","tag-obesity-drugs","tag-pharmaceutical-rivalry","tag-u-s-drug-market"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116974694313283697","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/134608","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=134608"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/134608\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/134609"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=134608"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=134608"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=134608"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}